|
US9745548B2
(en)
|
2012-03-15 |
2017-08-29 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
|
US9950282B2
(en)
|
2012-03-15 |
2018-04-24 |
Flodesign Sonics, Inc. |
Electronic configuration and control for acoustic standing wave generation
|
|
US9752113B2
(en)
|
2012-03-15 |
2017-09-05 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
|
US10704021B2
(en)
|
2012-03-15 |
2020-07-07 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
|
US10689609B2
(en)
|
2012-03-15 |
2020-06-23 |
Flodesign Sonics, Inc. |
Acoustic bioreactor processes
|
|
US10322949B2
(en)
|
2012-03-15 |
2019-06-18 |
Flodesign Sonics, Inc. |
Transducer and reflector configurations for an acoustophoretic device
|
|
US10967298B2
(en)
|
2012-03-15 |
2021-04-06 |
Flodesign Sonics, Inc. |
Driver and control for variable impedence load
|
|
US9458450B2
(en)
|
2012-03-15 |
2016-10-04 |
Flodesign Sonics, Inc. |
Acoustophoretic separation technology using multi-dimensional standing waves
|
|
US10737953B2
(en)
|
2012-04-20 |
2020-08-11 |
Flodesign Sonics, Inc. |
Acoustophoretic method for use in bioreactors
|
|
US9745569B2
(en)
|
2013-09-13 |
2017-08-29 |
Flodesign Sonics, Inc. |
System for generating high concentration factors for low cell density suspensions
|
|
WO2015105955A1
(en)
|
2014-01-08 |
2015-07-16 |
Flodesign Sonics, Inc. |
Acoustophoresis device with dual acoustophoretic chamber
|
|
CA2944528C
(en)
*
|
2014-04-03 |
2021-08-10 |
Cellectis |
Cd33 specific chimeric antigen receptors for cancer immunotherapy
|
|
AU2015248956B2
(en)
*
|
2014-04-14 |
2020-06-25 |
Cellectis |
BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
|
|
CA2946552A1
(en)
|
2014-04-25 |
2015-10-29 |
Bluebird Bio, Inc. |
Improved methods for manufacturing adoptive cell therapies
|
|
SG10201809379UA
(en)
|
2014-04-25 |
2018-11-29 |
Bluebird Bio Inc |
Mnd promoter chimeric antigen receptors
|
|
SMT202100049T1
(it)
|
2014-06-06 |
2021-03-15 |
Bluebird Bio Inc |
Composizioni di cellule t migliorate
|
|
US9744483B2
(en)
|
2014-07-02 |
2017-08-29 |
Flodesign Sonics, Inc. |
Large scale acoustic separation device
|
|
SG11201700492SA
(en)
*
|
2014-07-24 |
2017-02-27 |
Bluebird Bio Inc |
Bcma chimeric antigen receptors
|
|
JP6997620B2
(ja)
|
2014-12-05 |
2022-02-04 |
メモリアル スローン ケタリング キャンサー センター |
Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用
|
|
RS61781B1
(sr)
|
2014-12-05 |
2021-06-30 |
Memorial Sloan Kettering Cancer Center |
Antitela koja ciljaju antigen za sazrevanje b-ćelija i postupci upotrebe
|
|
WO2016094304A2
(en)
|
2014-12-12 |
2016-06-16 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
|
EP3250602A1
(en)
*
|
2015-01-26 |
2017-12-06 |
Cellectis |
T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
|
|
KR102349475B1
(ko)
|
2015-04-13 |
2022-01-11 |
화이자 인코포레이티드 |
B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
|
|
US11021699B2
(en)
|
2015-04-29 |
2021-06-01 |
FioDesign Sonics, Inc. |
Separation using angled acoustic waves
|
|
US11708572B2
(en)
|
2015-04-29 |
2023-07-25 |
Flodesign Sonics, Inc. |
Acoustic cell separation techniques and processes
|
|
US11377651B2
(en)
|
2016-10-19 |
2022-07-05 |
Flodesign Sonics, Inc. |
Cell therapy processes utilizing acoustophoresis
|
|
DK3298033T4
(da)
|
2015-05-18 |
2023-10-02 |
Tcr2 Therapeutics Inc |
Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner
|
|
EP3662909A1
(en)
|
2015-07-24 |
2020-06-10 |
Oncotracker, Inc. |
Gamma secretase modulators for the treatment of immune system dysfunction
|
|
US11474085B2
(en)
|
2015-07-28 |
2022-10-18 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
|
US11459540B2
(en)
|
2015-07-28 |
2022-10-04 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
WO2017075433A1
(en)
*
|
2015-10-30 |
2017-05-04 |
The Regents Of The University Of California |
Transforming growth factor-beta-responsive polypeptides and their methods for use
|
|
WO2017099712A1
(en)
|
2015-12-07 |
2017-06-15 |
Bluebird Bio, Inc. |
Improved t cell compositions
|
|
US11090334B2
(en)
|
2016-01-29 |
2021-08-17 |
Med Manor Organics (P) Ltd. |
Chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
|
|
CN116063503A
(zh)
*
|
2016-02-17 |
2023-05-05 |
思进股份有限公司 |
Bcma抗体和其用以治疗癌症和免疫病症的用途
|
|
EP3420077A4
(en)
*
|
2016-02-25 |
2019-12-25 |
Agenovir Corporation |
VIRAL AND ONCOVIRAL NUCLEASE TREATMENT
|
|
KR102397674B1
(ko)
*
|
2016-04-01 |
2022-05-18 |
카이트 파마 인코포레이티드 |
Bcma 결합 분자 및 그의 사용 방법
|
|
UA128781C2
(uk)
|
2016-04-01 |
2024-10-23 |
Кайт Фарма, Інк. |
Т-клітина, спосіб її отримання та застосування
|
|
SG11201808411RA
(en)
|
2016-04-01 |
2018-10-30 |
Kite Pharma Inc |
Chimeric antigen and t cell receptors and methods of use
|
|
US11085035B2
(en)
|
2016-05-03 |
2021-08-10 |
Flodesign Sonics, Inc. |
Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
|
|
US11214789B2
(en)
|
2016-05-03 |
2022-01-04 |
Flodesign Sonics, Inc. |
Concentration and washing of particles with acoustics
|
|
CA3064645C
(en)
*
|
2016-06-03 |
2023-06-27 |
Institut National De La Recherche Agronomique |
Diet controlled expression of a nucleic acid encoding a pro-apoptotic protein.
|
|
CN109641012A
(zh)
*
|
2016-06-07 |
2019-04-16 |
马克思-德布鲁克-分子医学中心亥姆霍兹联合会 |
与bcma结合的嵌合抗原受体和car-t细胞
|
|
US20190177421A1
(en)
*
|
2016-07-15 |
2019-06-13 |
Poseida Therapeutics, Inc. |
Chimeric antigen receptors and methods for use
|
|
JP7109789B2
(ja)
*
|
2016-08-02 |
2022-08-01 |
ティーシーアール２ セラピューティクス インク． |
融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
|
|
WO2018045325A1
(en)
|
2016-09-02 |
2018-03-08 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with duocars
|
|
BR112019007100A2
(pt)
|
2016-10-07 |
2019-06-25 |
Tcr2 Therapeutics Inc |
composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
|
|
EP3529347A1
(en)
|
2016-10-19 |
2019-08-28 |
Flodesign Sonics, Inc. |
Affinity cell extraction by acoustics
|
|
US12109234B2
(en)
|
2016-11-04 |
2024-10-08 |
2Seventy Bio, Inc. |
Anti-BCMA CAR T cell compositions
|
|
JP7291396B2
(ja)
|
2016-11-22 |
2023-06-15 |
ティーシーアール２ セラピューティクス インク． |
融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
|
|
US11286306B2
(en)
*
|
2016-12-09 |
2022-03-29 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
TLR9-binding chimeric antigen receptors
|
|
EP3577134A1
(en)
|
2017-01-31 |
2019-12-11 |
Novartis AG |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
|
KR20190116420A
(ko)
|
2017-02-17 |
2019-10-14 |
프레드 헛친슨 켄서 리서치 센터 |
Bcma 관련 암 및 자가면역 장애의 치료를 위한 조합 요법
|
|
DK3592379T3
(da)
*
|
2017-03-31 |
2024-06-03 |
Cellectis Sa |
Universelle anti-cd22-kimære antigenreceptor-modificerede immunceller
|
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
EP3622092A4
(en)
|
2017-05-11 |
2021-06-23 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
|
|
CN110914289B
(zh)
|
2017-05-12 |
2024-05-14 |
克里斯珀医疗股份公司 |
用于工程化细胞的材料和方法及其在免疫肿瘤学中的用途
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
CN119899277A
(zh)
*
|
2017-06-02 |
2025-04-29 |
辉瑞公司 |
靶向flt3的嵌合抗原受体
|
|
KR102693777B1
(ko)
|
2017-06-02 |
2024-08-08 |
화이자 인코포레이티드 |
Flt3에 특이적인 항체 및 이의 용도
|
|
US11897953B2
(en)
|
2017-06-14 |
2024-02-13 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
WO2019014581A1
(en)
|
2017-07-14 |
2019-01-17 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
|
|
WO2019046818A1
(en)
*
|
2017-09-01 |
2019-03-07 |
Dana-Farber Cancer Institute, Inc. |
SPECIFIC IMMUNOGENIC PEPTIDES OF BCMA AND TACI ANTIGENS FOR THE TREATMENT OF CANCER
|
|
US20200255526A1
(en)
|
2017-09-14 |
2020-08-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
EP3694878A1
(en)
|
2017-09-14 |
2020-08-19 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
CA3075716A1
(en)
|
2017-09-14 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
WO2019070755A1
(en)
|
2017-10-02 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
|
|
TWI829655B
(zh)
|
2017-10-18 |
2024-01-21 |
瑞士商諾華公司 |
用於選擇性蛋白質降解的組合物及方法
|
|
KR20200074997A
(ko)
|
2017-11-01 |
2020-06-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
|
|
TW201932482A
(zh)
*
|
2017-11-01 |
2019-08-16 |
美商奇諾治療有限公司 |
對b細胞成熟抗原具特異性之嵌合抗原受體及編碼聚核苷酸
|
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
|
CN111886012A
(zh)
|
2017-11-06 |
2020-11-03 |
朱诺治疗学股份有限公司 |
细胞疗法与γ分泌酶抑制剂的组合
|
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
|
WO2019094955A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
|
|
AU2018369883A1
(en)
|
2017-11-15 |
2020-05-28 |
Novartis Ag |
BCMA-targeting chimeric antigen receptor, CD19-targeting chimeric antigen receptor, and combination therapies
|
|
EP3489259A1
(en)
*
|
2017-11-23 |
2019-05-29 |
Etablissement Français du Sang |
Anti-il-1rap-car-t cells and their use
|
|
RU2020121458A
(ru)
|
2017-11-30 |
2021-12-30 |
Новартис Аг |
Химерный антигенный рецептор, нацеливающийся на bcma, и его пути применения
|
|
KR20220066413A
(ko)
|
2017-12-14 |
2022-05-24 |
프로디자인 소닉스, 인크. |
음향 트랜스듀서 구동기 및 제어기
|
|
CN118878697A
(zh)
|
2017-12-20 |
2024-11-01 |
波赛达治疗公司 |
Vcar组合物和使用方法
|
|
TW201930591A
(zh)
|
2018-01-08 |
2019-08-01 |
瑞士商諾華公司 |
用於與嵌合抗原受體療法併用之免疫增強rna
|
|
US20210038659A1
(en)
|
2018-01-31 |
2021-02-11 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
EP3757133A4
(en)
|
2018-02-11 |
2021-12-01 |
Jiangsu Hengrui Medicine Co., Ltd. |
ISOLATED ANTIGENIC CHEMICAL RECEPTOR, MODIFIED T LYMPHOCYTE INCLUDING IT AND ASSOCIATED USE
|
|
EP3752203A1
(en)
|
2018-02-13 |
2020-12-23 |
Novartis AG |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
CA3095864A1
(en)
*
|
2018-04-03 |
2019-10-10 |
Promab Biotechnologies, Inc. |
Bcma-car-t cells
|
|
CN116836297A
(zh)
|
2018-04-12 |
2023-10-03 |
上海赛比曼生物科技有限公司 |
靶向bcma的嵌合抗原受体及其制法和应用
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
IL278348B2
(en)
|
2018-05-11 |
2025-03-01 |
Crispr Therapeutics Ag |
Methods and preparations for treating cancer
|
|
KR20210057705A
(ko)
*
|
2018-06-01 |
2021-05-21 |
유니버시티 오브 써던 캘리포니아 |
세포 요법을 위한 다양한 항원 결합 도메인, 신규한 플랫폼 및 다른 향상
|
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
CN109021116B
(zh)
*
|
2018-08-16 |
2022-03-22 |
重庆精准生物技术有限公司 |
抗bcma抗原的嵌合抗原受体及其应用
|
|
CN109134665B
(zh)
*
|
2018-08-24 |
2021-06-11 |
上海先博生物科技有限公司 |
一种基于单域抗体的bcma嵌合抗原受体及应用
|
|
AU2019331496A1
(en)
|
2018-08-31 |
2021-03-18 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2020047449A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
|
WO2020092455A2
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
|
BR112021008055A2
(pt)
|
2018-10-31 |
2021-08-10 |
Glaxosmithkline Intellectual Property Development Limited |
métodos para determinar o prognóstico de câncer em um paciente, para prever uma resposta do paciente ao tratamento com uma proteína de ligação ao antígeno bcma, para selecionar a dose de uma proteína de ligação ao antígeno bcma e para diagnosticar câncer, composições farmacêuticas, kit e uso de uma proteína de ligação ao antígeno bcma para tratar câncer
|
|
SG11202104188VA
(en)
|
2018-11-01 |
2021-05-28 |
Juno Therapeutics Inc |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
|
BR112021007626A2
(pt)
|
2018-11-01 |
2021-10-13 |
Juno Therapeutics, Inc. |
Receptores antigênicos quiméricos específicos pa-ra receptor acoplado à proteína g receptor de classe c, grupo 5, membro d (gprc5d)
|
|
TW202039544A
(zh)
*
|
2018-12-01 |
2020-11-01 |
美商艾洛基因醫療公司 |
靶定ｂ細胞成熟抗原之嵌合抗原受體及其使用之方法
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
US20220152150A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
|
US12448429B2
(en)
|
2019-03-06 |
2025-10-21 |
Dana-Farber Cancer Institute, Inc. |
T cell receptors specific to b-cell maturation antigen for treatment of cancer
|
|
WO2020186101A1
(en)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
US20230074800A1
(en)
|
2019-03-21 |
2023-03-09 |
Novartis Ag |
Car-t cell therapies with enhanced efficacy
|
|
WO2020210678A1
(en)
|
2019-04-12 |
2020-10-15 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
EP3733707A1
(en)
*
|
2019-04-30 |
2020-11-04 |
Celyad S.A. |
Car t-cells targeting bcma and uses thereof
|
|
MX2021013359A
(es)
|
2019-04-30 |
2022-01-31 |
Crispr Therapeutics Ag |
Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19.
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
AU2020283027A1
(en)
|
2019-05-30 |
2021-12-23 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-BCMA immunotherapy
|
|
BR112022002236A2
(pt)
|
2019-08-06 |
2022-05-03 |
Glaxosmithkline Ip Dev Ltd |
Composições, composições farmacêuticas e uso das mesmas para tratar câncer, bem como formulações que compreendem as mesmas
|
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
JP2023501871A
(ja)
*
|
2019-09-20 |
2023-01-20 |
上海吉倍生物技術有限公司 |
Ｂｃｍａ標的化抗体及びキメラ抗原受容体
|
|
WO2021061791A1
(en)
*
|
2019-09-24 |
2021-04-01 |
The Regents Of The University Of California |
Notch receptors with zinc finger-containing transcriptional effector
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
CA3163104A1
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
|
WO2021118246A1
(en)
*
|
2019-12-10 |
2021-06-17 |
Abl Bio, Inc. |
Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
|
|
CN113045657B
(zh)
*
|
2019-12-26 |
2022-06-07 |
杭州济元基因科技有限公司 |
一种人源化抗人bcma单克隆抗体及其car-t细胞
|
|
WO2021144759A1
(en)
*
|
2020-01-17 |
2021-07-22 |
Crispr Therapeutics Ag |
Genetically engineered t cells expressing bcma-specific chimeric antigen receptors and uses thereof in cancer therapy
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
EP4110377A2
(en)
|
2020-02-27 |
2023-01-04 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
MX2022010604A
(es)
|
2020-02-27 |
2022-09-09 |
Novartis Ag |
Metodos de produccion de celulas que expresan receptores antigenicos quimericos.
|
|
CN112851815B
(zh)
*
|
2020-03-17 |
2023-08-08 |
西安宇繁生物科技有限责任公司 |
抗bcma抗体或其抗原结合片段及其制备方法和应用
|
|
CN115916223A
(zh)
|
2020-04-10 |
2023-04-04 |
朱诺治疗学股份有限公司 |
与用靶向b细胞成熟抗原的嵌合抗原受体工程化的细胞疗法相关的方法和用途
|
|
CN115667303A
(zh)
*
|
2020-04-14 |
2023-01-31 |
尤利乌斯·马克西米利安维尔茨堡大学 |
Atra或其他维甲酸与结合bcma的免疫治疗剂的联合疗法
|
|
CA3181399A1
(en)
|
2020-04-28 |
2021-11-04 |
Juno Therapeutics, Inc. |
Combination of bcma-directed t cell therapy and an immunomodulatory compound
|
|
CN113637073B
(zh)
*
|
2020-05-11 |
2024-04-12 |
上海赛比曼生物科技有限公司 |
Bcma抗体及其制备和应用
|
|
WO2021252920A1
(en)
|
2020-06-11 |
2021-12-16 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
CA3187267A1
(en)
|
2020-06-17 |
2021-12-23 |
Janssen Biotech, Inc. |
Materials and methods for the manufacture of pluripotent stem cells
|
|
WO2022040586A2
(en)
|
2020-08-21 |
2022-02-24 |
Novartis Ag |
Compositions and methods for in vivo generation of car expressing cells
|
|
WO2022056490A1
(en)
*
|
2020-09-14 |
2022-03-17 |
Vor Biopharma, Inc. |
Chimeric antigen receptors for treatment of cancer
|
|
CN112062864A
(zh)
*
|
2020-09-18 |
2020-12-11 |
樊克兴 |
靶向bcma肿瘤抗原受体修饰t细胞的制备方法和应用
|
|
AU2021401052A1
(en)
|
2020-12-18 |
2023-06-22 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
|
AU2022257093A1
(en)
|
2021-04-16 |
2023-11-02 |
Celgene Corporation |
T cell therapy in patients who have had prior stem cell transplant
|
|
CA3214683A1
(en)
|
2021-04-16 |
2022-10-20 |
Julie Ann RYTLEWSKI |
Combination therapies with bcma-directed t cell therapy
|
|
AR125468A1
(es)
|
2021-04-27 |
2023-07-19 |
Novartis Ag |
Sistema de producción de vectores virales
|
|
JP2024517863A
(ja)
|
2021-05-06 |
2024-04-23 |
ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
細胞を刺激し、形質導入する方法
|
|
US20250263495A1
(en)
|
2021-05-28 |
2025-08-21 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapies for Treating Cancer
|
|
WO2022266075A1
(en)
|
2021-06-14 |
2022-12-22 |
Caribou Biosciences, Inc. |
Methods and materials for treating cancer using car constructs with an intracellular domain comprising a stap domain and a kinase domain or a stap domain and a phosphatase domain
|
|
US20230174651A1
(en)
|
2021-06-23 |
2023-06-08 |
Janssen Biotech, Inc. |
Materials and methods for hinge regions in functional exogenous receptors
|
|
WO2023012669A2
(en)
|
2021-08-03 |
2023-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Biopharmaceutical compositions and stable isotope labeling peptide mapping method
|
|
EP4388000A1
(en)
|
2021-08-20 |
2024-06-26 |
Novartis AG |
Methods of making chimeric antigen receptor?expressing cells
|
|
JP2024537863A
(ja)
|
2021-10-05 |
2024-10-16 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
がんを処置するための組合せ療法
|
|
JP2024540320A
(ja)
|
2021-11-03 |
2024-10-31 |
セルジーン コーポレーション |
骨髄腫を処置する際に使用するための、ｂ細胞成熟抗原に特異的なキメラ抗原受容体
|
|
CN118591560A
(zh)
|
2022-01-25 |
2024-09-03 |
葛兰素史密斯克莱知识产权发展有限公司 |
癌症的组合疗法
|
|
JP2025504002A
(ja)
|
2022-01-28 |
2025-02-06 |
ジュノー セラピューティクス インコーポレイテッド |
細胞組成物を製造する方法
|
|
US20250297282A1
(en)
|
2022-05-05 |
2025-09-25 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
EP4522183A2
(en)
|
2022-05-11 |
2025-03-19 |
Celgene Corporation |
Methods and uses related to t cell therapy and production of same
|
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
EP4532695A1
(en)
|
2022-05-25 |
2025-04-09 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
CA3262611A1
(en)
|
2022-07-22 |
2024-01-25 |
Janssen Biotech, Inc. |
IMPROVED TRANSFER OF GENETIC INSTRUCTIONS TO EFFECTOR IMMUNE CELLS
|
|
KR20250047766A
(ko)
|
2022-08-05 |
2025-04-04 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Gprc5d 및 bcma에 특이적인 키메라 항원 수용체
|
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
|
WO2024089639A1
(en)
|
2022-10-26 |
2024-05-02 |
Novartis Ag |
Lentiviral formulations
|
|
EP4611798A1
(en)
|
2022-11-02 |
2025-09-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
JP2025540200A
(ja)
|
2022-12-05 |
2025-12-11 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
Ｂ細胞成熟抗原のアンタゴニストを使用する治療方法
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
AU2024214593A1
(en)
|
2023-02-03 |
2025-08-07 |
C3S2 Gmbh |
Methods for non-viral manufacturing of engineered immune cells
|
|
WO2024168192A1
(en)
|
2023-02-10 |
2024-08-15 |
Celgene Corporation |
Assessment of bcma in biological samples
|
|
WO2024197157A1
(en)
|
2023-03-21 |
2024-09-26 |
Biograph 55, Inc. |
Cd19/cd38 multispecific antibodies
|
|
EP4626447A1
(en)
|
2023-03-31 |
2025-10-08 |
AbelZeta Inc. |
Bispecific chimeric antigen receptors targeting cd20 and bcma
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2025076127A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
WO2025231185A1
(en)
|
2024-05-01 |
2025-11-06 |
Legend Biotech Ireland Limited |
Viral glycoprotein variants and uses thereof
|